(ARKG) ARK Genomic Revolution - Ratings and Ratios
Genomics, Gene, CRISPR, Health
Description: ARKG ARK Genomic Revolution
The ARK Genomic Revolution ETF (ARKG) is a US-based health sector ETF that focuses on genomic revolution companies, investing in firms that are leveraging genetic research to develop new treatments and therapies. The funds underlying holdings are likely to include companies involved in gene editing, gene therapy, and genetic diagnostics.
Key economic drivers for ARKG include advancements in genetic research, government support for genomics and biotechnology, and the growing demand for precision medicine. The funds performance is likely to be influenced by the progress of its underlying holdings in developing new treatments and therapies, as well as the overall sentiment towards the biotechnology and healthcare sectors.
To evaluate the funds performance, relevant KPIs could include metrics such as the number of pipeline drugs in development, the success rate of clinical trials, and the revenue growth of its underlying holdings. Additionally, the funds AUM of $989.80M USD suggests a moderate level of investor interest, and its liquidity profile, with an average volume of 2,165,700 shares, indicates that it is relatively easy to enter or exit positions.
The ETFs beta of 1.930 suggests that it is expected to be relatively volatile compared to the broader market, which may be a consideration for risk-averse investors. Overall, ARKGs performance is likely to be driven by the innovation and progress of its underlying holdings, as well as the overall trends in the biotechnology and healthcare sectors.
ARKG ETF Overview
| Market Cap in USD | 1,027m |
| Category | Health |
| TER | 0.75% |
| IPO / Inception | 2014-10-31 |
ARKG ETF Ratings
| Growth Rating | -42.1% |
| Fundamental | - |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | -16.3% |
| Analyst Rating | - |
ARKG Dividends
Currently no dividends paidARKG Growth Ratios
| Growth Correlation 3m | 26.6% |
| Growth Correlation 12m | -22% |
| Growth Correlation 5y | -93.1% |
| CAGR 5y | -9.97% |
| CAGR/Max DD 3y | -0.19 |
| CAGR/Mean DD 3y | -0.34 |
| Sharpe Ratio 12m | -0.20 |
| Alpha | -17.14 |
| Beta | 0.928 |
| Volatility | 35.65% |
| Current Volume | 2009.6k |
| Average Volume 20d | 1789.2k |
| Stop Loss | 25 (-3.6%) |
| Signal | 0.40 |
What is the price of ARKG shares?
Over the past week, the price has changed by +1.77%, over one month by +2.73%, over three months by +8.40% and over the past year by -0.46%.
Is ARK Genomic Revolution a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARKG is around 21.35 USD . This means that ARKG is currently overvalued and has a potential downside of -17.66%.
Is ARKG a buy, sell or hold?
What are the forecasts/targets for the ARKG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24 | -7.4% |
Last update: 2025-09-05 04:32
ARKG Fundamental Data Overview
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 USD
Beta = 1.93
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.03b USD (1.03b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 1.03b)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.03b / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(1.03b)/V(0.0) * Re(9.43%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.43% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for ARKG ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle